The US Department of Defense’s (DoD) Committee on Tactical Combat Casualty Care (CoTCCC) has approved the use of Celox Gauze as a haemostatic agent on the battlefield.
The decision, which follows testing of five treatments by the US Navy, adds Celox Gauze to all wound care and medical kits used by the US military.
The testing confirmed that it had the highest rate of survivability, highest overall haemostasis, as well as the least overall blood loss compared to other existing treatments.
Celox Gauze is a high density gauze designed to stop catastrophic arterial bleeding, which is believed to be the leading cause of preventable death on the battlefield, within three minutes.
Available in 5ft z-folded packs for individual first aid kits and 10ft z-fold and rolls for the medic or vehicle kit, the bandage contains Celox granules to act on the most severe bleeding in challenging conditions, including wind, rain or poor visibility.
In many of the worst injuries, the blood lost causes the body’s natural clotting abilities to fail, but Celox acts independently of the body’s mechanism and continues to work in this situation.
Medtrade Haemostats marketing head Chris Marsden said Celox works alongside other innovations from the Iraq and Afghanistan conflicts, such as the new tourniquets and drugs that help to keep blood clots intact.
"It stops bleeding with simple pressure and is simple and rugged for front-line use," Marsden said.
Celox Gauze, which has been approved by the US Food and Drug Administration (FDA), is also used by UK and other International Security Assistance Force (ISAF) troops.
Image: The Celox family of haemostatic products are designed to treat severe bleeding in a variety of wounds. Photo: courtesy of BioStat, LLC.